Skip to search formSkip to main contentSkip to account menu

BYL719

Known as: Phosphoinositide 3-kinase Inhibitor BYL719 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AlpelisibNVP-BYL719

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
2500Background: Phosphatidylinositol-3-kinase (PI3K) and fibroblast growth factor receptor (FGFR) pathway dysregulation can co… 
2016
2016
SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.
TPS618Background: The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently… 
2015
2015
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
SummaryPurposeKRAS is frequently mutated in non-small cell lung cancers (NSCLC), resulting in activation of the MEK/ERK pathway… 
2015
2015
Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer
Background: BYL719 selectively inhibits the α-isoform of Class I PI3K. PI3Kα is encoded by PIK3CA, a frequently altered gene in… 
2015
2015
Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).
Nasopharyngeal carcinoma (NPC) is endemic to Southeast Asia and over 40% of NPC tissues harbor PIK3CA amplifications. This study… 
2015
2015
Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Background: Phosphatidylinositol 3-kinase (PI3K) hyperactivation plays a role in endocrine therapy resistance. Adding an… 
2014
2014
Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).
533 Background: Postmenopausal women with advanced ER+ BC are usually treated with aromatase inhibitors (AIs) as first-line… 
2014
2014
Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
143 Background: Activation of the PI3K/AKT/mTOR and cyclin D-CDK4/6-INK4-Rb pathways has been implicated in endocrine therapy… 
2013
2013
Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Defining predictive biomarkers and deriving… 
2013
2013
Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study
Background: Phosphatidylinositol-3-kinase (PI3K) pathway activation has been associated with resistance to anti-estrogen receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)